139 related articles for article (PubMed ID: 36780635)
1. Initial Experience With Biosimilar Bevacizumab-bvzr For Intravitreal Use in Children: A Case Series and Literature Review.
Jung EE; Lee TC; Nagiel A
Ophthalmic Surg Lasers Imaging Retina; 2023 Feb; 54(2):84-88. PubMed ID: 36780635
[TBL] [Abstract][Full Text] [Related]
2. Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection.
Peraza MA; Hurst S; Huang W; Buetow BS; Lickteig AJ; Lavach JD; Frost DF; Collins ME; Sellers RS; Matsumoto Smith D
J Ocul Pharmacol Ther; 2023 Apr; 39(3):215-224. PubMed ID: 36880872
[No Abstract] [Full Text] [Related]
3. Intravitreal low-dosage bevacizumab for retinopathy of prematurity.
Harder BC; von Baltz S; Jonas JB; Schlichtenbrede FC
Acta Ophthalmol; 2014 Sep; 92(6):577-81. PubMed ID: 24020921
[TBL] [Abstract][Full Text] [Related]
4. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
5. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma.
Higashide T; Murotani E; Saito Y; Ohkubo S; Sugiyama K
Graefes Arch Clin Exp Ophthalmol; 2012 Apr; 250(4):603-10. PubMed ID: 22116499
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series.
Roohipoor R; Ghasemi H; Ghassemi F; Karkhaneh R; Riazi-Esfahani M; Nili-Ahmadabadi M
Graefes Arch Clin Exp Ophthalmol; 2011 Sep; 249(9):1295-301. PubMed ID: 21494873
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels.
Lee JY; Chae JB; Yang SJ; Yoon YH; Kim JG
Graefes Arch Clin Exp Ophthalmol; 2010 Sep; 248(9):1257-62. PubMed ID: 20393741
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration.
Aisenbrey S; Ziemssen F; Völker M; Gelisken F; Szurman P; Jaissle G; Grisanti S; Bartz-Schmidt KU
Graefes Arch Clin Exp Ophthalmol; 2007 Jul; 245(7):941-8. PubMed ID: 17186262
[TBL] [Abstract][Full Text] [Related]
9. Real-world usage of bevacizumab-bvzr biosimilar in US oncology practice.
Yang J; Kelton JM; Thompson J; Alvir JMJ; Maculaitis MC; Shelbaya A
Am J Manag Care; 2022 Apr; 28(4):160-166. PubMed ID: 35420744
[TBL] [Abstract][Full Text] [Related]
10. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
11. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
12. The effect of intravitreal bevacizumab injection as the initial treatment for Coats' disease.
Zheng XX; Jiang YR
Graefes Arch Clin Exp Ophthalmol; 2014 Jan; 252(1):35-42. PubMed ID: 23873253
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
14. A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity.
Khodabande A; Niyousha MR; Roohipoor R
J AAPOS; 2016 Dec; 20(6):490-492. PubMed ID: 27794470
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage.
Nazari H; Modarres M; Parvaresh MM; Ghasemi Falavarjani K
Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1713-8. PubMed ID: 20582706
[TBL] [Abstract][Full Text] [Related]
16. Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy.
Henaine-Berra A; Garcia-Aguirre G; Quiroz-Mercado H; Martinez-Castellanos MA
J AAPOS; 2014 Apr; 18(2):120-3. PubMed ID: 24698606
[TBL] [Abstract][Full Text] [Related]
17. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.
Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG
Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566
[TBL] [Abstract][Full Text] [Related]
18. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
Smith JM; Steel DH
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
[TBL] [Abstract][Full Text] [Related]
20. Treatment of choroidal neovascularization using intravitreal bevacizumab.
Pedersen R; Soliman W; Lund-Andersen H; Larsen M
Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]